Navigation Links
Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
Date:11/9/2007

PITTSBURGH Nov. 9, 2007 Researchers at Childrens Hospital of Pittsburgh of UPMC are participating in an international clinical trial currently underway to study the effectiveness of oral insulin in preventing or delaying the onset of type 1 diabetes in people at risk for the disease.

The researchers want to determine if one insulin capsule taken daily can prevent or delay the onset of type 1 diabetes in relatives of people who are found to be at risk for developing the disease, according to Dorothy Becker, MBBCh, chief of the Division of Pediatric Diabetes and Endocrinology at Childrens and principal investigator of the study.

An earlier trial called Diabetes Prevention Trial 1, conducted at Childrens and other centers around the world, suggested that oral insulin might delay type 1 diabetes by about four years in some people with auto-antibodies to insulin in their blood. Oral insulin has no known side effects.

Type 1 diabetes is a very difficult disease to manage. Because it typically begins in childhood or young adulthood, and if not properly controlled with insulin injections and diet and exercise, diabetes can lead to a lifetime of complications that can cause chronic disability and be life-threatening, said Dr. Becker. If oral insulin could delay the onset or prevent the disease, we could spare these patients years of difficult management and potential complications such as heart disease and vision loss.

The oral insulin study is being conducted at more than 150 sites throughout the world by TrialNet, a network of diabetes research centers of which Childrens and UPMC are members. At Childrens, researchers plan to enroll at least 30 relatives of patients with type 1 diabetes (parents, siblings, children, cousins, uncles and aunts) ages 3 45 to study the effectiveness of oral insulin.

The belief is that insulin introduced via the digestive tract may induce tolerance, quieting the immune systems attack on itse
'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
2. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
3. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
4. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
5. Studying component parts of living cells with carbon nanotube cellular probes
6. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
7. Researchers studying how singing bats communicate
8. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
9. Neuronal conduction of excitation without action potentials based on ceramide production
10. To maximize biofuel potential, researchers look for sorghums sweet spot
11. Joslin researchers uncover potential role of leptin in diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... that protects metals against corrosion in seawater has ... Sheffield Hallam University. At the Society for General ... Jeanette Gittens and colleagues described how they had ... coating which then protected an aluminium alloy from ...
... Institutes of Health (NIH) researchers have identified a gene that ... cancer. The finding is reported today in the journal ... of a group of enzymes implicated in skin cancer and ... found that one-quarter of human melanoma tumors had changes, or ...
... insight into mechanisms that allow invasive tumor cells to move, ... new understanding about how to stop cancer from spreading. A ... is the process that most often leads to death from ... Nature Cell Biology , researchers say that a molecule ...
Cached Biology News:Skin cancer study uncovers new tumor suppressor gene 2Skin cancer study uncovers new tumor suppressor gene 3Mayo Clinic researchers discover and manipulate molecular interplay that moves cancer cells 2
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jspg2c/global_biologics ... "Global Biologics and Biosimilars Industry Report 2015" ... The Global Biologics and Biosimilars Industry Report 2015 ... current state of the biologics and biosimilars industry. ... of the industry including definitions, classifications, applications and ...
(Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
(Date:3/4/2015)... 4, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... pain, today announced that it will release fourth ... close on Monday, March 9th, 2015. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
(Date:3/4/2015)... March 4, 2015 Vegalab announced the acquisition ... of last year. As part of the acquisition, Ecowin ... continuing his role as CEO for the company,s ... S.A., will work alongside Koo and oversee developments at ... http://photos.prnewswire.com/prnh/20150303/179218 Koo founded Ecowin in ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3
... the atomic forces that cause friction, thanks to a ... Pennsylvania, the University of Houston and the U.S. Department ... by Robert Carpick of the University of Pennsylvania, found ... that had been coated with different isotopes of hydrogen ...
... CARMIEL, Israel, Nov. 2 Protalix,BioTherapeutics, Inc. (Amex: ... Aviezer,Ph.D., its President and Chief Executive Officer, will ... Conference. Dr. Aviezer,s presentation,will take place at 3:00 ... Hotel in New York City. Dr. Aviezer,s ...
... Confirmed, REINACH and BASEL, Switzerland, November 2 ... on its late-stage,investigational antibiotic iclaprim at the 9th ... VKliPha) which takes place,1-3 November in Kiel, Germany. ... substantial volume of data on iclaprim that is ...
Cached Biology Technology:Heavier hydrogen on the atomic scale reduces friction 2Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 3Arpida Presents Data on Iclaprim at Scientific Congress in Germany 4
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... TOPO Cloning is the ... for cloning PCR products. ... Zero Blunt TOPO vectors ... activated with topoisomerase I. ...
Applications: ISH...
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
Biology Products: